Chinese Firm Warned for Data Integrity, Record Maintenance Issues

Drug GMP Report
A A
The FDA issued a warning letter to Jilin Shulan after an inspection of the firm’s Shulan City, Jilin Province facility revealed significant GMP deviations for active pharmaceutical ingredients.

To View This Article:

Login

Subscribe To Drug GMP Report